Prostate cancer drug shows promise against COVID

Researchers look into a drug called proxalutamide as a potential therapeutic for the coronavirus

5:00 AM

Author | Kelly Malcom

pill attacking coronavirus
Getty Images

Want to listen to this article instead? Check out this episode on Health Lab's podcast. And check out the Health Lab podcast page and subscribe to listen on Apple PodcastsStitcher or wherever you listen to podcasts.

At the outset of the COVID pandemic, men appeared to suffer higher rates of severe illness and death, leading researchers to suspect a link between androgen receptors—which bind to hormones like testosterone—and SARS-CoV-2 viral infection.

This observation spurred Michigan Medicine researchers to look into a drug in development to treat prostate cancer called proxalutamide, which works by blocking an enzyme called TMPRSS2 (transmembrane protease, serine 2) that is regulated by androgen receptors, as a potential therapeutic for COVID.

“We were already studying TMPRSS2 as part of the key gene driver of over 50 percent of prostate cancer, so it made sense to look at it as TMPRSS2 is an important host factor for SARS-CoV2 to enter cells in the lung,” said Arul Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology and the S.P. Hicks Endowed Professor of Pathology.

Chinnaiyan, co-principal investigator Jonathan Sexton, Ph.D., assistant professor of Internal Medicine at the University of Michigan Medical School and Assistant professor of medicinal chemistry in the College of Pharmacy and their team recently published their study in PNAS.

The team added proxalutamide to cells infected with SARS-Co-V2 to monitor its ability to block viral entry.

The compound works by binding to androgen receptors, inhibiting levels of TMPRSS2 and ACE2, and blocking infection.

What’s more, proxalutamide worked better than other prostate cancer drugs against multiple variants of SARS-CoV2 due to its ability to break down the androgen receptor.

Additionally, proxalutamide, when combined with FDA-approved COVID drug remdesivir, blocked infection by 100%.

“This discovery underscores the utility of testing existing drugs for new applications that can be rapidly evaluated in humans to shorten the timeline from discovery to clinical evaluation," said Sexton, who is also director of the U-M Center for Drug Repurposing.

Buoyed by their in vitro results, the team looked to see whether the compound could stop the so-called cytokine storm, or severe inflammatory response, caused by SARS-CoV-2 infection.

Using a mouse model, they demonstrated that the drug reduced inflammation and cell death in the lungs of mice and reduced mortality.

Said Chinnaiyan, “The thought is proxalutamide could work as a combined therapy with remdesivir, hitting the virus from multiple angles, much as combination therapy works so well for HIV infection.”

The drug is currently in phase 3 clinical trials for prostate cancer and early clinical trials for COVID.

Additional authors: Yuanyuan Qiao, Jesse W. Wotring, Yang Zheng, Charles J. Zhang, Yuping Zhang, Xia Jiang, Carla D. Pretto, Sanjana Eyunni, Abhijit Parolia, Tongchen He, Caleb Cheng, Xuhong Cao, Rui Wang, Fengyun Su, Stephanie J. Ellison, Yini Wang, Jun Qin, Honghua Yan, Qianxiang Zhou, Liandong Ma

Paper cited: “Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response,” PNAS. DOI: 10.1073/pnas.2221809120


More Articles About: Preventative health and wellness Covid-19 COVID-19 Vaccine Prostate Cancer Prostate Conditions Community Health Vaccines and Immunizations
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories little girl sitting on grass watching fireworks
Health Lab
7 tips for a safer Fourth of July fireworks show
An emergency physician shares firework safety tips. He recommends a clear lighting area and following instructions.
Patient at desk drinking a fluid
Health Lab
5 hot weather tips that could save an older adult’s life
Health professionals offer five tips to help older adults stay safe and healthy during excessive heat wave.
Cancer Aware
Focal therapy for prostate cancer
When treating for localized prostate cancer, surgery and radiation are usually what people hear about. However, there are other treatments that could be options under a heading of focal therapy. Dr. Andrew Wood, a urologic oncologist with U-M Health Rogel Cancer Center’s Weiser Center for Prostate Cancer talks about these options and which patients could benefit from them.
Microscopic view of lung cells: The lungs are patrolled by specialized adaptive immune cells called CD4+ T cells that constantly interact with distinct lung epithelial cells to ensure our lungs are protected from pathogens.
Department News
What we do in M&I? "Adaptive Immunology"
In M&I, we study adaptive immunology, also known as acquired immunology. The adaptive system is highly specific in that it distinguishes between different agents, recognizes a previously encountered agent, and adapts its response accordingly. When that agent is a pathogen, the adaptive response can help to clear that infection. A key feature of adaptive immunity is the development of immunological memory. This is the biology behind vaccines.
father and son standing together and book cover
Health Lab
One doctor’s American dream: to stop hate
Asian-American history is American history. William D. Chey shares his immigrant father’s legacy, his own experience and calls on youth to practice the values of diversity, equity and inclusion throughout their lives.
cells purple some lighter cells in white
Health Lab
Researchers find early driver of prostate cancer aggressiveness
University of Michigan Health Rogel Cancer Center scientists identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form. The gene can be indirectly targeted with an existing class of drugs, suggesting a potential treatment strategy for patients with aggressive subtypes of prostate cancer.